ZA200403000B - Glycoprotein compositions. - Google Patents

Info

Publication number

ZA200403000B

ZA200403000B ZA200403000A ZA200403000A ZA200403000B ZA 200403000 B ZA200403000 B ZA 200403000B ZA 200403000 A ZA200403000 A ZA 200403000A ZA 200403000 A ZA200403000 A ZA 200403000A ZA 200403000 B ZA200403000 B ZA 200403000B

Authority

ZA

South Africa

Prior art keywords

glycoprotein

composition

region

antibody

human

Prior art date

2001-10-25

Links

• Espacenet
• Global Dossier
• Discuss

• 102000003886 Glycoproteins Human genes 0.000 title claims description 234
• 108090000288 Glycoproteins Proteins 0.000 title claims description 234
• 239000000203 mixture Substances 0.000 title claims description 97
• 210000004027 cell Anatomy 0.000 claims description 240
• 241000282414 Homo sapiens Species 0.000 claims description 176
• 239000000427 antigen Substances 0.000 claims description 105
• 108091007433 antigens Proteins 0.000 claims description 103
• 102000036639 antigens Human genes 0.000 claims description 103
• 238000000034 method Methods 0.000 claims description 98
• 235000001014 amino acid Nutrition 0.000 claims description 84
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 72
• 206010028980 Neoplasm Diseases 0.000 claims description 66
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 64
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 48
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 48
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 46
• 238000006467 substitution reaction Methods 0.000 claims description 46
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 44
• 201000011510 cancer Diseases 0.000 claims description 41
• 150000001720 carbohydrates Chemical group 0.000 claims description 35
• 150000007523 nucleic acids Chemical class 0.000 claims description 34
• 102000004190 Enzymes Human genes 0.000 claims description 32
• 108090000790 Enzymes Proteins 0.000 claims description 32
• 102000039446 nucleic acids Human genes 0.000 claims description 31
• 108020004707 nucleic acids Proteins 0.000 claims description 31
• 241000124008 Mammalia Species 0.000 claims description 29
• 239000003814 drug Substances 0.000 claims description 27
• 201000010099 disease Diseases 0.000 claims description 22
• 208000035475 disorder Diseases 0.000 claims description 22
• 238000004519 manufacturing process Methods 0.000 claims description 21
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 20
• OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 claims description 19
• OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 18
• MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 18
• 229940127089 cytotoxic agent Drugs 0.000 claims description 17
• 210000001519 tissue Anatomy 0.000 claims description 17
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 16
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 16
• 238000011282 treatment Methods 0.000 claims description 14
• 235000004279 alanine Nutrition 0.000 claims description 12
• 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 12
• 208000023275 Autoimmune disease Diseases 0.000 claims description 10
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 10
• 238000004113 cell culture Methods 0.000 claims description 10
• 241000699802 Cricetulus griseus Species 0.000 claims description 8
• 102000001301 EGF receptor Human genes 0.000 claims description 8
• 108060006698 EGF receptor Proteins 0.000 claims description 8
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 8
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 8
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 8
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 8
• 230000008901 benefit Effects 0.000 claims description 8
• 239000002254 cytotoxic agent Substances 0.000 claims description 8
• 208000027866 inflammatory disease Diseases 0.000 claims description 8
• 210000001672 ovary Anatomy 0.000 claims description 8
• 125000005629 sialic acid group Chemical group 0.000 claims description 8
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 7
• 231100000599 cytotoxic agent Toxicity 0.000 claims description 7
• 101710120463 Prostate stem cell antigen Proteins 0.000 claims description 6
• 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 6
• 238000012258 culturing Methods 0.000 claims description 6
• 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 5
• 208000015181 infectious disease Diseases 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 4
• 239000002458 cell surface marker Substances 0.000 claims description 3
• 230000001268 conjugating effect Effects 0.000 claims description 3
• 239000002870 angiogenesis inducing agent Substances 0.000 claims description 2
• OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 2
• 229950006780 n-acetylglucosamine Drugs 0.000 claims 2
• 108010063916 CD40 Antigens Proteins 0.000 claims 1
• 230000027455 binding Effects 0.000 description 168
• 108090000765 processed proteins & peptides Proteins 0.000 description 113
• 102000004196 processed proteins & peptides Human genes 0.000 description 102
• 229920001184 polypeptide Polymers 0.000 description 99
• 108090000623 proteins and genes Proteins 0.000 description 69
• 102000005962 receptors Human genes 0.000 description 67
• 108020003175 receptors Proteins 0.000 description 67
• 108060003951 Immunoglobulin Proteins 0.000 description 51
• 102000018358 immunoglobulin Human genes 0.000 description 51
• 125000000837 carbohydrate group Chemical group 0.000 description 50
• 229940024606 amino acid Drugs 0.000 description 49
• 150000001413 amino acids Chemical class 0.000 description 49
• 230000000694 effects Effects 0.000 description 48
• 108010087819 Fc receptors Proteins 0.000 description 47
• 102000009109 Fc receptors Human genes 0.000 description 47
• 230000004048 modification Effects 0.000 description 45
• 238000012986 modification Methods 0.000 description 45
• 235000018102 proteins Nutrition 0.000 description 44
• 102000004169 proteins and genes Human genes 0.000 description 44
• 125000000539 amino acid group Chemical group 0.000 description 38
• 230000006870 function Effects 0.000 description 36
• 150000002482 oligosaccharides Chemical class 0.000 description 35
• 230000001976 improved effect Effects 0.000 description 34
• 229920001542 oligosaccharide Polymers 0.000 description 34
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 33
• 239000012636 effector Substances 0.000 description 31
• 229940088598 enzyme Drugs 0.000 description 31
• 238000003556 assay Methods 0.000 description 29
• -1 G-1 oligosaccharide Chemical class 0.000 description 28
• 238000006206 glycosylation reaction Methods 0.000 description 28
• 230000013595 glycosylation Effects 0.000 description 27
• 230000014509 gene expression Effects 0.000 description 26
• 229940002612 prodrug Drugs 0.000 description 26
• 239000000651 prodrug Substances 0.000 description 26
• 108020004414 DNA Proteins 0.000 description 25
• 235000014633 carbohydrates Nutrition 0.000 description 25
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 24
• 229940079593 drug Drugs 0.000 description 23
• 210000004408 hybridoma Anatomy 0.000 description 21
• 239000003446 ligand Substances 0.000 description 21
• 239000013598 vector Substances 0.000 description 21
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 20
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 20
• 230000000295 complement effect Effects 0.000 description 19
• 230000004927 fusion Effects 0.000 description 19
• 230000002829 reductive effect Effects 0.000 description 19
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 18
• 241001529936 Murinae Species 0.000 description 18
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 18
• 230000001225 therapeutic effect Effects 0.000 description 18
• 230000012010 growth Effects 0.000 description 17
• 238000002360 preparation method Methods 0.000 description 17
• 239000003795 chemical substances by application Substances 0.000 description 16
• 239000000306 component Substances 0.000 description 16
• 239000012634 fragment Substances 0.000 description 16
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 15
• 206010035226 Plasma cell myeloma Diseases 0.000 description 15
• 239000002246 antineoplastic agent Substances 0.000 description 15
• 238000003780 insertion Methods 0.000 description 15
• 230000037431 insertion Effects 0.000 description 15
• 241001465754 Metazoa Species 0.000 description 14
• 230000004913 activation Effects 0.000 description 14
• 230000002401 inhibitory effect Effects 0.000 description 14
• 201000000050 myeloid neoplasm Diseases 0.000 description 14
• 210000002966 serum Anatomy 0.000 description 14
• 241000699666 Mus <mouse, genus> Species 0.000 description 13
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 13
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 13
• 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 13
• 239000002502 liposome Substances 0.000 description 13
• 230000001404 mediated effect Effects 0.000 description 13
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 12
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 12
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 12
• 230000004071 biological effect Effects 0.000 description 12
• 229930182830 galactose Natural products 0.000 description 12
• 238000001727 in vivo Methods 0.000 description 12
• 230000001965 increasing effect Effects 0.000 description 12
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 12
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
• 239000000758 substrate Substances 0.000 description 12
• 235000000346 sugar Nutrition 0.000 description 12
• 210000004881 tumor cell Anatomy 0.000 description 12
• 239000004471 Glycine Substances 0.000 description 11
• 108010022394 Threonine synthase Proteins 0.000 description 11
• 238000004458 analytical method Methods 0.000 description 11
• 210000004369 blood Anatomy 0.000 description 11
• 239000008280 blood Substances 0.000 description 11
• 102000004419 dihydrofolate reductase Human genes 0.000 description 11
• 229940088597 hormone Drugs 0.000 description 11
• 239000005556 hormone Substances 0.000 description 11
• 238000000338 in vitro Methods 0.000 description 11
• 125000005647 linker group Chemical group 0.000 description 11
• 229960004641 rituximab Drugs 0.000 description 11
• 206010006187 Breast cancer Diseases 0.000 description 10
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 10
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 10
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 10
• 238000010367 cloning Methods 0.000 description 10
• 230000002950 deficient Effects 0.000 description 10
• 239000003623 enhancer Substances 0.000 description 10
• 229940072221 immunoglobulins Drugs 0.000 description 10
• 241000894007 species Species 0.000 description 10
• 239000003053 toxin Substances 0.000 description 10
• 231100000765 toxin Toxicity 0.000 description 10
• 108700012359 toxins Proteins 0.000 description 10
• 238000013518 transcription Methods 0.000 description 10
• 230000035897 transcription Effects 0.000 description 10
• 208000026310 Breast neoplasm Diseases 0.000 description 9
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 9
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 9
• 239000004473 Threonine Substances 0.000 description 9
• 230000000875 corresponding effect Effects 0.000 description 9
• 239000003102 growth factor Substances 0.000 description 9
• 239000001963 growth medium Substances 0.000 description 9
• 210000000265 leukocyte Anatomy 0.000 description 9
• 238000012545 processing Methods 0.000 description 9
• 238000000746 purification Methods 0.000 description 9
• 241000894006 Bacteria Species 0.000 description 8
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 8
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
• 108010076504 Protein Sorting Signals Proteins 0.000 description 8
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 8
• 239000002253 acid Substances 0.000 description 8
• 230000015572 biosynthetic process Effects 0.000 description 8
• 231100000433 cytotoxic Toxicity 0.000 description 8
• 230000001472 cytotoxic effect Effects 0.000 description 8
• 238000012217 deletion Methods 0.000 description 8
• 230000037430 deletion Effects 0.000 description 8
• 239000013604 expression vector Substances 0.000 description 8
• 229940127121 immunoconjugate Drugs 0.000 description 8
• 239000002609 medium Substances 0.000 description 8
• 230000002018 overexpression Effects 0.000 description 8
• 239000000047 product Substances 0.000 description 8
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
• 108091026890 Coding region Proteins 0.000 description 7
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 7
• 102000004127 Cytokines Human genes 0.000 description 7
• 108090000695 Cytokines Proteins 0.000 description 7
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 7
• 241000588724 Escherichia coli Species 0.000 description 7
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 7
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 7
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 7
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 7
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 7
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 7
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
• 230000004075 alteration Effects 0.000 description 7
• 238000013459 approach Methods 0.000 description 7
• SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 7
• HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 7
• 230000003247 decreasing effect Effects 0.000 description 7
• 238000009472 formulation Methods 0.000 description 7
• 230000001900 immune effect Effects 0.000 description 7
• 210000004962 mammalian cell Anatomy 0.000 description 7
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 7
• 239000003094 microcapsule Substances 0.000 description 7
• 230000002285 radioactive effect Effects 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 239000004474 valine Substances 0.000 description 7
• 235000014393 valine Nutrition 0.000 description 7
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
• QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 description 6
• JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 6
• JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 6
• 201000004624 Dermatitis Diseases 0.000 description 6
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 6
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
• 108090001090 Lectins Proteins 0.000 description 6
• 102000004856 Lectins Human genes 0.000 description 6
• 108010054377 Mannosidases Proteins 0.000 description 6
• 102000001696 Mannosidases Human genes 0.000 description 6
• 108091028043 Nucleic acid sequence Proteins 0.000 description 6
• 241000700605 Viruses Species 0.000 description 6
• 230000003213 activating effect Effects 0.000 description 6
• 239000000872 buffer Substances 0.000 description 6
• 229930195731 calicheamicin Natural products 0.000 description 6
• 230000030833 cell death Effects 0.000 description 6
• 150000001875 compounds Chemical class 0.000 description 6
• 230000001086 cytosolic effect Effects 0.000 description 6
• 230000001419 dependent effect Effects 0.000 description 6
• 239000000539 dimer Substances 0.000 description 6
• LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 6
• 238000005516 engineering process Methods 0.000 description 6
• 229960002949 fluorouracil Drugs 0.000 description 6
• 108020001507 fusion proteins Proteins 0.000 description 6
• 102000037865 fusion proteins Human genes 0.000 description 6
• 235000001727 glucose Nutrition 0.000 description 6
• 230000002163 immunogen Effects 0.000 description 6
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
• 239000002523 lectin Substances 0.000 description 6
• 239000003550 marker Substances 0.000 description 6
• 230000004060 metabolic process Effects 0.000 description 6
• 229960000485 methotrexate Drugs 0.000 description 6
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
• 210000001616 monocyte Anatomy 0.000 description 6
• 210000000822 natural killer cell Anatomy 0.000 description 6
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
• 230000010076 replication Effects 0.000 description 6
• 238000012552 review Methods 0.000 description 6
• 230000002269 spontaneous effect Effects 0.000 description 6
• 150000008163 sugars Chemical class 0.000 description 6
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
• 230000003612 virological effect Effects 0.000 description 6
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 5
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 5
• 206010009944 Colon cancer Diseases 0.000 description 5
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 5
• 102000004877 Insulin Human genes 0.000 description 5
• 108090001061 Insulin Proteins 0.000 description 5
• 108010063738 Interleukins Proteins 0.000 description 5
• 102000015696 Interleukins Human genes 0.000 description 5
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 5
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
• 241000699670 Mus sp. Species 0.000 description 5
• 230000004988 N-glycosylation Effects 0.000 description 5
• 239000002202 Polyethylene glycol Substances 0.000 description 5
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
• 239000004365 Protease Substances 0.000 description 5
• 241000283984 Rodentia Species 0.000 description 5
• 210000001744 T-lymphocyte Anatomy 0.000 description 5
• 108010000499 Thromboplastin Proteins 0.000 description 5
• 102000002262 Thromboplastin Human genes 0.000 description 5
• 239000003242 anti bacterial agent Substances 0.000 description 5
• 230000003466 anti-cipated effect Effects 0.000 description 5
• 229940088710 antibiotic agent Drugs 0.000 description 5
• 125000004429 atom Chemical group 0.000 description 5
• 230000001588 bifunctional effect Effects 0.000 description 5
• 210000004899 c-terminal region Anatomy 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 230000024203 complement activation Effects 0.000 description 5
• 239000002299 complementary DNA Substances 0.000 description 5
• 239000000356 contaminant Substances 0.000 description 5
• 230000002255 enzymatic effect Effects 0.000 description 5
• 239000008103 glucose Substances 0.000 description 5
• 230000036541 health Effects 0.000 description 5
• 102000006495 integrins Human genes 0.000 description 5
• 108010044426 integrins Proteins 0.000 description 5
• 150000002632 lipids Chemical class 0.000 description 5
• 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 5
• 239000012528 membrane Substances 0.000 description 5
• 210000004379 membrane Anatomy 0.000 description 5
• 230000037361 pathway Effects 0.000 description 5
• 102000013415 peroxidase activity proteins Human genes 0.000 description 5
• 108040007629 peroxidase activity proteins Proteins 0.000 description 5
• 239000013612 plasmid Substances 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 238000003752 polymerase chain reaction Methods 0.000 description 5
• 230000005180 public health Effects 0.000 description 5
• 238000010188 recombinant method Methods 0.000 description 5
• 238000011160 research Methods 0.000 description 5
• 239000000523 sample Substances 0.000 description 5
• 230000028327 secretion Effects 0.000 description 5
• SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 5
• 208000011580 syndromic disease Diseases 0.000 description 5
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 108090001008 Avidin Proteins 0.000 description 4
• 102100038080 B-cell receptor CD22 Human genes 0.000 description 4
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 4
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 4
• 101150013553 CD40 gene Proteins 0.000 description 4
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 4
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 4
• 208000017667 Chronic Disease Diseases 0.000 description 4
• 102000007644 Colony-Stimulating Factors Human genes 0.000 description 4
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 4
• SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
• LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• 241000196324 Embryophyta Species 0.000 description 4
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 4
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 4
• 241000235649 Kluyveromyces Species 0.000 description 4
• 239000004472 Lysine Substances 0.000 description 4
• 108090000157 Metallothionein Proteins 0.000 description 4
• 108010025020 Nerve Growth Factor Proteins 0.000 description 4
• 108090000099 Neurotrophin-4 Proteins 0.000 description 4
• 230000004989 O-glycosylation Effects 0.000 description 4
• 229910019142 PO4 Inorganic materials 0.000 description 4
• 102000035195 Peptidases Human genes 0.000 description 4
• 108091005804 Peptidases Proteins 0.000 description 4
• 102100024952 Protein CBFA2T1 Human genes 0.000 description 4
• 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 4
• 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 4
• 108020004511 Recombinant DNA Proteins 0.000 description 4
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
• 201000009594 Systemic Scleroderma Diseases 0.000 description 4
• 206010042953 Systemic sclerosis Diseases 0.000 description 4
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
• 238000001042 affinity chromatography Methods 0.000 description 4
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 4
• 229940041181 antineoplastic drug Drugs 0.000 description 4
• 235000009582 asparagine Nutrition 0.000 description 4
• 229960001230 asparagine Drugs 0.000 description 4
• 210000003169 central nervous system Anatomy 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 238000004587 chromatography analysis Methods 0.000 description 4
• 229940047120 colony stimulating factors Drugs 0.000 description 4
• 230000021615 conjugation Effects 0.000 description 4
• 229920001577 copolymer Polymers 0.000 description 4
• 239000003431 cross linking reagent Substances 0.000 description 4
• 235000018417 cysteine Nutrition 0.000 description 4
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
• 231100000135 cytotoxicity Toxicity 0.000 description 4
• 230000003292 diminished effect Effects 0.000 description 4
• 238000012377 drug delivery Methods 0.000 description 4
• 238000013467 fragmentation Methods 0.000 description 4
• 238000006062 fragmentation reaction Methods 0.000 description 4
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
• 230000028993 immune response Effects 0.000 description 4
• 210000000987 immune system Anatomy 0.000 description 4
• 230000016784 immunoglobulin production Effects 0.000 description 4
• 230000006872 improvement Effects 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 229940047122 interleukins Drugs 0.000 description 4
• 210000003734 kidney Anatomy 0.000 description 4
• 210000003292 kidney cell Anatomy 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
• 239000010452 phosphate Substances 0.000 description 4
• 239000002243 precursor Substances 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
• 238000000159 protein binding assay Methods 0.000 description 4
• 150000003384 small molecules Chemical class 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
• 239000011573 trace mineral Substances 0.000 description 4
• 235000013619 trace mineral Nutrition 0.000 description 4
• 238000013519 translation Methods 0.000 description 4
• 241000701161 unidentified adenovirus Species 0.000 description 4
• JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 3
• GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 3
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
• 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 3
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
• 102000009027 Albumins Human genes 0.000 description 3
• 108010088751 Albumins Proteins 0.000 description 3
• 102000000412 Annexin Human genes 0.000 description 3
• 108050008874 Annexin Proteins 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 201000009030 Carcinoma Diseases 0.000 description 3
• 102000000844 Cell Surface Receptors Human genes 0.000 description 3
• 108010001857 Cell Surface Receptors Proteins 0.000 description 3
• 206010009900 Colitis ulcerative Diseases 0.000 description 3
• 108020004635 Complementary DNA Proteins 0.000 description 3
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
• 108010053770 Deoxyribonucleases Proteins 0.000 description 3
• 102000016911 Deoxyribonucleases Human genes 0.000 description 3
• 102000003951 Erythropoietin Human genes 0.000 description 3
• 108090000394 Erythropoietin Proteins 0.000 description 3
• 241000206602 Eukaryota Species 0.000 description 3
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
• 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
• 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
• 102000006471 Fucosyltransferases Human genes 0.000 description 3
• 108010019236 Fucosyltransferases Proteins 0.000 description 3
• 241000233866 Fungi Species 0.000 description 3
• 102000005744 Glycoside Hydrolases Human genes 0.000 description 3
• 108010031186 Glycoside Hydrolases Proteins 0.000 description 3
• 102220485264 Golgin subfamily A member 6A_K334A_mutation Human genes 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 3
• 108010000521 Human Growth Hormone Proteins 0.000 description 3
• 102000002265 Human Growth Hormone Human genes 0.000 description 3
• 239000000854 Human Growth Hormone Substances 0.000 description 3
• 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 3
• 108010073807 IgG Receptors Proteins 0.000 description 3
• 102000009490 IgG Receptors Human genes 0.000 description 3
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
• 108090001007 Interleukin-8 Proteins 0.000 description 3
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
• 108010000817 Leuprolide Proteins 0.000 description 3
• 102000009151 Luteinizing Hormone Human genes 0.000 description 3
• 108010073521 Luteinizing Hormone Proteins 0.000 description 3
• QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 description 3
• 102000003792 Metallothionein Human genes 0.000 description 3
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
• 238000005481 NMR spectroscopy Methods 0.000 description 3
• 229930193140 Neomycin Natural products 0.000 description 3
• 102000007072 Nerve Growth Factors Human genes 0.000 description 3
• 108090000526 Papain Proteins 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 3
• 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 3
• 230000018199 S phase Effects 0.000 description 3
• 206010040047 Sepsis Diseases 0.000 description 3
• 241000607720 Serratia Species 0.000 description 3
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 3
• 102000011923 Thyrotropin Human genes 0.000 description 3
• 108010061174 Thyrotropin Proteins 0.000 description 3
• 102000004357 Transferases Human genes 0.000 description 3
• 108090000992 Transferases Proteins 0.000 description 3
• 102100040247 Tumor necrosis factor Human genes 0.000 description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
• 201000006704 Ulcerative Colitis Diseases 0.000 description 3
• 206010047115 Vasculitis Diseases 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 3
• 230000003321 amplification Effects 0.000 description 3
• 230000002494 anti-cea effect Effects 0.000 description 3
• 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 3
• 208000006673 asthma Diseases 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• 229960002685 biotin Drugs 0.000 description 3
• 235000020958 biotin Nutrition 0.000 description 3
• 239000011616 biotin Substances 0.000 description 3
• 108010006025 bovine growth hormone Proteins 0.000 description 3
• 238000012511 carbohydrate analysis Methods 0.000 description 3
• 230000010261 cell growth Effects 0.000 description 3
• 210000000170 cell membrane Anatomy 0.000 description 3
• 239000003593 chromogenic compound Substances 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 238000004590 computer program Methods 0.000 description 3
• 239000007822 coupling agent Substances 0.000 description 3
• 238000004132 cross linking Methods 0.000 description 3
• 239000013078 crystal Substances 0.000 description 3
• 230000009089 cytolysis Effects 0.000 description 3
• 230000003013 cytotoxicity Effects 0.000 description 3
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 238000006471 dimerization reaction Methods 0.000 description 3
• 229940105423 erythropoietin Drugs 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 229940126864 fibroblast growth factor Drugs 0.000 description 3
• 238000002509 fluorescent in situ hybridization Methods 0.000 description 3
• 229940028334 follicle stimulating hormone Drugs 0.000 description 3
• 210000004602 germ cell Anatomy 0.000 description 3
• 229960002989 glutamic acid Drugs 0.000 description 3
• 239000003316 glycosidase inhibitor Substances 0.000 description 3
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
• 210000004754 hybrid cell Anatomy 0.000 description 3
• 229910052739 hydrogen Inorganic materials 0.000 description 3
• 239000001257 hydrogen Substances 0.000 description 3
• 230000008676 import Effects 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 229940125396 insulin Drugs 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
• 230000000302 ischemic effect Effects 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• 238000005304 joining Methods 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 208000014018 liver neoplasm Diseases 0.000 description 3
• 210000004072 lung Anatomy 0.000 description 3
• 229940040129 luteinizing hormone Drugs 0.000 description 3
• 230000003211 malignant effect Effects 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
• 229930182817 methionine Natural products 0.000 description 3
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
• 239000004005 microsphere Substances 0.000 description 3
• 150000002772 monosaccharides Chemical class 0.000 description 3
• 230000035772 mutation Effects 0.000 description 3
• 229960004927 neomycin Drugs 0.000 description 3
• 210000000440 neutrophil Anatomy 0.000 description 3
• 238000003199 nucleic acid amplification method Methods 0.000 description 3
• 239000002773 nucleotide Substances 0.000 description 3
• 125000003729 nucleotide group Chemical group 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 229940055729 papain Drugs 0.000 description 3
• 235000019834 papain Nutrition 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 210000004180 plasmocyte Anatomy 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
• 238000003156 radioimmunoprecipitation Methods 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000010410 reperfusion Effects 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• 102220227378 rs863224873 Human genes 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 230000003248 secreting effect Effects 0.000 description 3
• 206010041823 squamous cell carcinoma Diseases 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 230000005030 transcription termination Effects 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 238000009966 trimming Methods 0.000 description 3
• 238000011144 upstream manufacturing Methods 0.000 description 3
• 229960004528 vincristine Drugs 0.000 description 3
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
• VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 2
• LXBIFEVIBLOUGU-FSIIMWSLSA-N 1-Deoxymannojirimycin Natural products OC[C@@H]1NC[C@@H](O)[C@H](O)[C@H]1O LXBIFEVIBLOUGU-FSIIMWSLSA-N 0.000 description 2
• GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
• YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 2
• 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 2
• LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical class NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 2
• VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
• OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
• 229940117976 5-hydroxylysine Drugs 0.000 description 2
• 108010051457 Acid Phosphatase Proteins 0.000 description 2
• 102000013563 Acid Phosphatase Human genes 0.000 description 2
• 108010059616 Activins Proteins 0.000 description 2
• 102000005606 Activins Human genes 0.000 description 2
• 229920000936 Agarose Polymers 0.000 description 2
• 101710154825 Aminoglycoside 3'-phosphotransferase Proteins 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 206010003445 Ascites Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 241000194108 Bacillus licheniformis Species 0.000 description 2
• 201000001178 Bacterial Pneumonia Diseases 0.000 description 2
• 208000009137 Behcet syndrome Diseases 0.000 description 2
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
• 108010006654 Bleomycin Proteins 0.000 description 2
• 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
• 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
• 241000701822 Bovine papillomavirus Species 0.000 description 2
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
• 229940045513 CTLA4 antagonist Drugs 0.000 description 2
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 108010084457 Cathepsins Proteins 0.000 description 2
• 102000005600 Cathepsins Human genes 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 102100022641 Coagulation factor IX Human genes 0.000 description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
• 241000699800 Cricetinae Species 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
• 230000004544 DNA amplification Effects 0.000 description 2
• 108010092160 Dactinomycin Proteins 0.000 description 2
• 206010012438 Dermatitis atopic Diseases 0.000 description 2
• 206010051392 Diapedesis Diseases 0.000 description 2
• 241000255925 Diptera Species 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 206010014733 Endometrial cancer Diseases 0.000 description 2
• 206010014759 Endometrial neoplasm Diseases 0.000 description 2
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
• 229930189413 Esperamicin Natural products 0.000 description 2
• 108010076282 Factor IX Proteins 0.000 description 2
• 108010054218 Factor VIII Proteins 0.000 description 2
• 102000001690 Factor VIII Human genes 0.000 description 2
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• LQEBEXMHBLQMDB-UHFFFAOYSA-N GDP-L-fucose Natural products OC1C(O)C(O)C(C)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C3=C(C(N=C(N)N3)=O)N=C2)O1 LQEBEXMHBLQMDB-UHFFFAOYSA-N 0.000 description 2
• LQEBEXMHBLQMDB-JGQUBWHWSA-N GDP-beta-L-fucose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1 LQEBEXMHBLQMDB-JGQUBWHWSA-N 0.000 description 2
• 102000006395 Globulins Human genes 0.000 description 2
• 108010044091 Globulins Proteins 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 2
• 102100022624 Glucoamylase Human genes 0.000 description 2
• 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 2
• 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 2
• ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
• 244000068988 Glycine max Species 0.000 description 2
• 235000010469 Glycine max Nutrition 0.000 description 2
• 102000006771 Gonadotropins Human genes 0.000 description 2
• 108010086677 Gonadotropins Proteins 0.000 description 2
• 108010051696 Growth Hormone Proteins 0.000 description 2
• 102220507621 Heat shock factor protein 4_S298A_mutation Human genes 0.000 description 2
• 208000009889 Herpes Simplex Diseases 0.000 description 2
• 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 2
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
• 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 2
• 108091006905 Human Serum Albumin Proteins 0.000 description 2
• 102000008100 Human Serum Albumin Human genes 0.000 description 2
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
• 206010021138 Hypovolaemic shock Diseases 0.000 description 2
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
• 208000028622 Immune thrombocytopenia Diseases 0.000 description 2
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
• 102100025390 Integrin beta-2 Human genes 0.000 description 2
• 238000012695 Interfacial polymerization Methods 0.000 description 2
• 102000006992 Interferon-alpha Human genes 0.000 description 2
• 108010047761 Interferon-alpha Proteins 0.000 description 2
• 102000014150 Interferons Human genes 0.000 description 2
• 108010050904 Interferons Proteins 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• 108090000174 Interleukin-10 Proteins 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 108010002386 Interleukin-3 Proteins 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• 108010002616 Interleukin-5 Proteins 0.000 description 2
• 108090001005 Interleukin-6 Proteins 0.000 description 2
• 108010002586 Interleukin-7 Proteins 0.000 description 2
• 108010002335 Interleukin-9 Proteins 0.000 description 2
• ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 2
• 102100020880 Kit ligand Human genes 0.000 description 2
• 244000285963 Kluyveromyces fragilis Species 0.000 description 2
• 241001138401 Kluyveromyces lactis Species 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 2
• 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 2
• 108090001030 Lipoproteins Proteins 0.000 description 2
• 102000004895 Lipoproteins Human genes 0.000 description 2
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
• 230000027311 M phase Effects 0.000 description 2
• 239000004907 Macro-emulsion Substances 0.000 description 2
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
• 201000009906 Meningitis Diseases 0.000 description 2
• 229930192392 Mitomycin Natural products 0.000 description 2
• 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
• 108090000028 Neprilysin Proteins 0.000 description 2
• 102000003729 Neprilysin Human genes 0.000 description 2
• 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
• 108090000742 Neurotrophin 3 Proteins 0.000 description 2
• 102100029268 Neurotrophin-3 Human genes 0.000 description 2
• 102000003683 Neurotrophin-4 Human genes 0.000 description 2
• 102100033857 Neurotrophin-4 Human genes 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 description 2
• 102000004316 Oxidoreductases Human genes 0.000 description 2
• 108090000854 Oxidoreductases Proteins 0.000 description 2
• 102000003982 Parathyroid hormone Human genes 0.000 description 2
• 108090000445 Parathyroid hormone Proteins 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 108010001014 Plasminogen Activators Proteins 0.000 description 2
• 102000001938 Plasminogen Activators Human genes 0.000 description 2
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 108010076181 Proinsulin Proteins 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 101800004937 Protein C Proteins 0.000 description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 239000012980 RPMI-1640 medium Substances 0.000 description 2
• 238000011529 RT qPCR Methods 0.000 description 2
• 208000006265 Renal cell carcinoma Diseases 0.000 description 2
• 206010063837 Reperfusion injury Diseases 0.000 description 2
• 108020005091 Replication Origin Proteins 0.000 description 2
• 108010039491 Ricin Proteins 0.000 description 2
• 102400000827 Saposin-D Human genes 0.000 description 2
• 101800001700 Saposin-D Proteins 0.000 description 2
• 102000012479 Serine Proteases Human genes 0.000 description 2
• 108010022999 Serine Proteases Proteins 0.000 description 2
• 108010071390 Serum Albumin Proteins 0.000 description 2
• 102000007562 Serum Albumin Human genes 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 241000700584 Simplexvirus Species 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 102100038803 Somatotropin Human genes 0.000 description 2
• 238000002105 Southern blotting Methods 0.000 description 2
• 241000256251 Spodoptera frugiperda Species 0.000 description 2
• 108010039445 Stem Cell Factor Proteins 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
• 229940123237 Taxane Drugs 0.000 description 2
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
• 102000036693 Thrombopoietin Human genes 0.000 description 2
• 108010041111 Thrombopoietin Proteins 0.000 description 2
• 102000006601 Thymidine Kinase Human genes 0.000 description 2
• 108020004440 Thymidine kinase Proteins 0.000 description 2
• 102100031372 Thymidine phosphorylase Human genes 0.000 description 2
• 108700023160 Thymidine phosphorylases Proteins 0.000 description 2
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
• 108010009583 Transforming Growth Factors Proteins 0.000 description 2
• 102000009618 Transforming Growth Factors Human genes 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
• 206010046851 Uveitis Diseases 0.000 description 2
• 244000000188 Vaccinium ovalifolium Species 0.000 description 2
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 239000000488 activin Substances 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 206010069351 acute lung injury Diseases 0.000 description 2
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
• 150000001299 aldehydes Chemical class 0.000 description 2
• 125000000217 alkyl group Chemical group 0.000 description 2
• 230000000961 alloantigen Effects 0.000 description 2
• 108010061314 alpha-L-Fucosidase Proteins 0.000 description 2
• 102000012086 alpha-L-Fucosidase Human genes 0.000 description 2
• 229960003896 aminopterin Drugs 0.000 description 2
• 239000003098 androgen Substances 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 238000005571 anion exchange chromatography Methods 0.000 description 2
• 230000003432 anti-folate effect Effects 0.000 description 2
• 230000036436 anti-hiv Effects 0.000 description 2
• 230000003388 anti-hormonal effect Effects 0.000 description 2
• 210000000628 antibody-producing cell Anatomy 0.000 description 2
• 229940127074 antifolate Drugs 0.000 description 2
• 230000000890 antigenic effect Effects 0.000 description 2
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 235000003704 aspartic acid Nutrition 0.000 description 2
• 201000008937 atopic dermatitis Diseases 0.000 description 2
• 208000010668 atopic eczema Diseases 0.000 description 2
• 244000052616 bacterial pathogen Species 0.000 description 2
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
• 239000003114 blood coagulation factor Substances 0.000 description 2
• 229940112869 bone morphogenetic protein Drugs 0.000 description 2
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
• 239000001354 calcium citrate Substances 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
• 239000006143 cell culture medium Substances 0.000 description 2
• 230000011712 cell development Effects 0.000 description 2
• 230000006037 cell lysis Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 229960004630 chlorambucil Drugs 0.000 description 2
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 229960004316 cisplatin Drugs 0.000 description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
• 238000005354 coacervation Methods 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
• 229960003901 dacarbazine Drugs 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 229960000975 daunorubicin Drugs 0.000 description 2
• 239000003405 delayed action preparation Substances 0.000 description 2
• YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 238000002059 diagnostic imaging Methods 0.000 description 2
• 238000000502 dialysis Methods 0.000 description 2
• 239000010432 diamond Substances 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 229960005156 digoxin Drugs 0.000 description 2
• 125000005442 diisocyanate group Chemical group 0.000 description 2
• ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 206010014599 encephalitis Diseases 0.000 description 2
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 230000006862 enzymatic digestion Effects 0.000 description 2
• 229960001904 epirubicin Drugs 0.000 description 2
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
• YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 2
• 239000005038 ethylene vinyl acetate Substances 0.000 description 2
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
• 229960004222 factor ix Drugs 0.000 description 2
• 229950003499 fibrin Drugs 0.000 description 2
• XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 2
• 229960004413 flucytosine Drugs 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• 150000002222 fluorine compounds Chemical class 0.000 description 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
• 239000004052 folic acid antagonist Substances 0.000 description 2
• 230000003325 follicular Effects 0.000 description 2
• 230000005714 functional activity Effects 0.000 description 2
• UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
• CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
• 238000001502 gel electrophoresis Methods 0.000 description 2
• 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
• 239000002622 gonadotropin Substances 0.000 description 2
• 239000000122 growth hormone Substances 0.000 description 2
• 201000009277 hairy cell leukemia Diseases 0.000 description 2
• 230000002440 hepatic effect Effects 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 239000000017 hydrogel Substances 0.000 description 2
• 150000002431 hydrogen Chemical class 0.000 description 2
• 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 2
• 238000012872 hydroxylapatite chromatography Methods 0.000 description 2
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 229960001101 ifosfamide Drugs 0.000 description 2
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
• 150000002463 imidates Chemical class 0.000 description 2
• 239000012642 immune effector Substances 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 238000003119 immunoblot Methods 0.000 description 2
• 229940121354 immunomodulator Drugs 0.000 description 2
• 238000001114 immunoprecipitation Methods 0.000 description 2
• 230000002637 immunotoxin Effects 0.000 description 2
• 229940051026 immunotoxin Drugs 0.000 description 2
• 239000002596 immunotoxin Substances 0.000 description 2
• 231100000608 immunotoxin Toxicity 0.000 description 2
• 238000005462 in vivo assay Methods 0.000 description 2
• 230000008595 infiltration Effects 0.000 description 2
• 238000001764 infiltration Methods 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 239000000893 inhibin Substances 0.000 description 2
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 150000002484 inorganic compounds Chemical class 0.000 description 2
• 229910010272 inorganic material Inorganic materials 0.000 description 2
• 229940079322 interferon Drugs 0.000 description 2
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
• 229960004338 leuprorelin Drugs 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 201000007270 liver cancer Diseases 0.000 description 2
• 210000005229 liver cell Anatomy 0.000 description 2
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 230000036210 malignancy Effects 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
• 229960004961 mechlorethamine Drugs 0.000 description 2
• 229960001428 mercaptopurine Drugs 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
• 239000004530 micro-emulsion Substances 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• 229960001156 mitoxantrone Drugs 0.000 description 2
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
• 239000000178 monomer Substances 0.000 description 2
• 208000037890 multiple organ injury Diseases 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 229960000951 mycophenolic acid Drugs 0.000 description 2
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
• 239000002088 nanocapsule Substances 0.000 description 2
• 108010068617 neonatal Fc receptor Proteins 0.000 description 2
• 239000003900 neurotrophic factor Substances 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 235000015097 nutrients Nutrition 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• 239000002751 oligonucleotide probe Substances 0.000 description 2
• 238000011275 oncology therapy Methods 0.000 description 2
• 230000002138 osteoinductive effect Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 230000001590 oxidative effect Effects 0.000 description 2
• 239000000199 parathyroid hormone Substances 0.000 description 2
• 229960001319 parathyroid hormone Drugs 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
• 210000001322 periplasm Anatomy 0.000 description 2
• 238000002823 phage display Methods 0.000 description 2
• 239000008194 pharmaceutical composition Substances 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 150000003904 phospholipids Chemical class 0.000 description 2
• 210000002826 placenta Anatomy 0.000 description 2
• 229940127126 plasminogen activator Drugs 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
• 230000008488 polyadenylation Effects 0.000 description 2
• 208000005987 polymyositis Diseases 0.000 description 2
• 229920001451 polypropylene glycol Polymers 0.000 description 2
• 230000001323 posttranslational effect Effects 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 108010087851 prorelaxin Proteins 0.000 description 2
• 235000019833 protease Nutrition 0.000 description 2
• 229960000856 protein c Drugs 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 229960004622 raloxifene Drugs 0.000 description 2
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
• 238000003259 recombinant expression Methods 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 239000011347 resin Substances 0.000 description 2
• 229920005989 resin Polymers 0.000 description 2
• GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 201000000306 sarcoidosis Diseases 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 206010040560 shock Diseases 0.000 description 2
• 235000017281 sodium acetate Nutrition 0.000 description 2
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
• 239000000243 solution Substances 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 210000001082 somatic cell Anatomy 0.000 description 2
• 230000006641 stabilisation Effects 0.000 description 2
• 238000011105 stabilization Methods 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
• JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• 229960001603 tamoxifen Drugs 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 125000000101 thioether group Chemical group 0.000 description 2
• CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 2
• 229960001196 thiotepa Drugs 0.000 description 2
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 229940104230 thymidine Drugs 0.000 description 2
• 229960003087 tioguanine Drugs 0.000 description 2
• 229960000187 tissue plasminogen activator Drugs 0.000 description 2
• 229960005267 tositumomab Drugs 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 230000031998 transcytosis Effects 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 230000009261 transgenic effect Effects 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• 239000002753 trypsin inhibitor Substances 0.000 description 2
• 238000000108 ultra-filtration Methods 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
• 229960003048 vinblastine Drugs 0.000 description 2
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
• 239000011782 vitamin Substances 0.000 description 2
• 229940088594 vitamin Drugs 0.000 description 2
• 235000013343 vitamin Nutrition 0.000 description 2
• 229930003231 vitamin Natural products 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
• SUCAFEYLYXXTPF-SSGXUJNVSA-N (1r,2s,3r)-6-bromocyclohex-4-ene-1,2,3-triol Chemical compound O[C@@H]1C=CC(Br)[C@H](O)[C@H]1O SUCAFEYLYXXTPF-SSGXUJNVSA-N 0.000 description 1
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
• FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
• XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
• KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
• CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 1
• XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
• IEUUDEWWMRQUDS-UHFFFAOYSA-N (6-azaniumylidene-1,6-dimethoxyhexylidene)azanium;dichloride Chemical compound Cl.Cl.COC(=N)CCCCC(=N)OC IEUUDEWWMRQUDS-UHFFFAOYSA-N 0.000 description 1
• XRBSKUSTLXISAB-UHFFFAOYSA-N (7R,7'R,8R,8'R)-form-Podophyllic acid Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C(CO)C2C(O)=O)=C1 XRBSKUSTLXISAB-UHFFFAOYSA-N 0.000 description 1
• AESVUZLWRXEGEX-DKCAWCKPSA-N (7S,9R)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione iron(3+) Chemical compound [Fe+3].COc1cccc2C(=O)c3c(O)c4C[C@@](O)(C[C@H](O[C@@H]5C[C@@H](N)[C@@H](O)[C@@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO AESVUZLWRXEGEX-DKCAWCKPSA-N 0.000 description 1
• JXVAMODRWBNUSF-KZQKBALLSA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
• AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
• UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
• FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
• HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
• PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• MVMSCBBUIHUTGJ-UHFFFAOYSA-N 10108-97-1 Natural products C1=2NC(N)=NC(=O)C=2N=CN1C(C(C1O)O)OC1COP(O)(=O)OP(O)(=O)OC1OC(CO)C(O)C(O)C1O MVMSCBBUIHUTGJ-UHFFFAOYSA-N 0.000 description 1
• BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
• KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical class C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 1
• BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
• YGPWNPKDCKXDHE-UHFFFAOYSA-N 2-(2,5-dioxopyrrolidin-1-yl)-4-pyridin-2-ylsulfanylpentanoic acid Chemical compound C=1C=CC=NC=1SC(C)CC(C(O)=O)N1C(=O)CCC1=O YGPWNPKDCKXDHE-UHFFFAOYSA-N 0.000 description 1
• BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
• FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
• FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
• QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
• VNBAOSVONFJBKP-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)propan-1-amine;hydrochloride Chemical compound Cl.CC(Cl)CN(CCCl)CCCl VNBAOSVONFJBKP-UHFFFAOYSA-N 0.000 description 1
• XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
• AOPRXJXHLWYPQR-UHFFFAOYSA-N 2-phenoxyacetamide Chemical class NC(=O)COC1=CC=CC=C1 AOPRXJXHLWYPQR-UHFFFAOYSA-N 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
• HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
• QXZBMSIDSOZZHK-DOPDSADYSA-N 31362-50-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CNC=N1 QXZBMSIDSOZZHK-DOPDSADYSA-N 0.000 description 1
• WHVTZNGCKIEGPC-UHFFFAOYSA-N 4-(4-aminophenyl)-2,2,6,6-tetramethylcyclohex-3-en-1-amine;hydrochloride Chemical compound Cl.CC1(C)C(N)C(C)(C)CC(C=2C=CC(N)=CC=2)=C1 WHVTZNGCKIEGPC-UHFFFAOYSA-N 0.000 description 1
• RQKYYWBMXHYBAP-UHFFFAOYSA-N 4-(chloromethyl)-2,2-dimethyl-1,3,2-dioxasilolane Chemical compound C[Si]1(C)OCC(CCl)O1 RQKYYWBMXHYBAP-UHFFFAOYSA-N 0.000 description 1
• XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
• DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
• HRDVWDQQYABHGH-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-N,N-dimethylaniline hydrochloride Chemical compound Cl.CN(C)c1ccc(cc1)-c1ccc(cc1)N(C)C HRDVWDQQYABHGH-UHFFFAOYSA-N 0.000 description 1
• DMIUGJLERMOBNT-UHFFFAOYSA-N 4-amino-n-(3-methoxypyrazin-2-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 DMIUGJLERMOBNT-UHFFFAOYSA-N 0.000 description 1
• 108010029607 4-nitrophenyl-alpha-glucosidase Proteins 0.000 description 1
• 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
• 102100022464 5'-nucleotidase Human genes 0.000 description 1
• IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
• FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
• WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
• 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
• 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
• AIQMLBKBQCVDEY-UHFFFAOYSA-N 7-epi-australine Natural products OC1CCN2C(CO)C(O)C(O)C21 AIQMLBKBQCVDEY-UHFFFAOYSA-N 0.000 description 1
• ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
• HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
• 108010066676 Abrin Proteins 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 102100036664 Adenosine deaminase Human genes 0.000 description 1
• GVNWZKBFMFUVNX-UHFFFAOYSA-N Adipamide Chemical compound NC(=O)CCCCC(N)=O GVNWZKBFMFUVNX-UHFFFAOYSA-N 0.000 description 1
• 241000256118 Aedes aegypti Species 0.000 description 1
• 241000256173 Aedes albopictus Species 0.000 description 1
• 101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
• 101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
• 206010027654 Allergic conditions Diseases 0.000 description 1
• CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
• 206010001889 Alveolitis Diseases 0.000 description 1
• QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
• 108090000672 Annexin A5 Proteins 0.000 description 1
• 102000004121 Annexin A5 Human genes 0.000 description 1
• 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
• 101710081722 Antitrypsin Proteins 0.000 description 1
• 102100029361 Aromatase Human genes 0.000 description 1
• 108010078554 Aromatase Proteins 0.000 description 1
• 102000009133 Arylsulfatases Human genes 0.000 description 1
• 241000228212 Aspergillus Species 0.000 description 1
• 241000351920 Aspergillus nidulans Species 0.000 description 1
• 241000228245 Aspergillus niger Species 0.000 description 1
• 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
• 206010003497 Asphyxia Diseases 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
• 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
• 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
• AIQMLBKBQCVDEY-OZRXBMAMSA-N Australine Chemical compound O[C@H]1CCN2[C@H](CO)[C@@H](O)[C@H](O)[C@H]21 AIQMLBKBQCVDEY-OZRXBMAMSA-N 0.000 description 1
• AIQMLBKBQCVDEY-FMGWEMOISA-N Australine Natural products O[C@@H]1CCN2[C@@H](CO)[C@H](O)[C@H](O)[C@H]21 AIQMLBKBQCVDEY-FMGWEMOISA-N 0.000 description 1
• 241001203868 Autographa californica Species 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
• 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
• 241000713842 Avian sarcoma virus Species 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• 108091008875 B cell receptors Proteins 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 108090000363 Bacterial Luciferases Proteins 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 208000027496 Behcet disease Diseases 0.000 description 1
• VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
• 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
• 102000013585 Bombesin Human genes 0.000 description 1
• 108010051479 Bombesin Proteins 0.000 description 1
• 241000255789 Bombyx mori Species 0.000 description 1
• 241000409811 Bombyx mori nucleopolyhedrovirus Species 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 206010048962 Brain oedema Diseases 0.000 description 1
• 206010006458 Bronchitis chronic Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 102100031092 C-C motif chemokine 3 Human genes 0.000 description 1
• 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
• 102000002110 C2 domains Human genes 0.000 description 1
• 108050009459 C2 domains Proteins 0.000 description 1
• 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
• 108010036239 CD4-IgG(2) Proteins 0.000 description 1
• 108010065524 CD52 Antigen Proteins 0.000 description 1
• 108010009575 CD55 Antigens Proteins 0.000 description 1
• 102100027221 CD81 antigen Human genes 0.000 description 1
• 102100027217 CD82 antigen Human genes 0.000 description 1
• 102100035793 CD83 antigen Human genes 0.000 description 1
• 102400000113 Calcitonin Human genes 0.000 description 1
• 108060001064 Calcitonin Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
• 108010006303 Carboxypeptidases Proteins 0.000 description 1
• 102000005367 Carboxypeptidases Human genes 0.000 description 1
• AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
• 241000282552 Chlorocebus aethiops Species 0.000 description 1
• MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
• 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
• 108090000746 Chymosin Proteins 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 102100032768 Complement receptor type 2 Human genes 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• 102000000311 Cytosine Deaminase Human genes 0.000 description 1
• 108010080611 Cytosine Deaminase Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
• 150000008574 D-amino acids Chemical group 0.000 description 1
• LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
• 239000012624 DNA alkylating agent Substances 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 101710088194 Dehydrogenase Proteins 0.000 description 1
• 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
• NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 101001030665 Dictyostelium discoideum GDP-L-fucose synthase Proteins 0.000 description 1
• LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
• 108090000204 Dipeptidase 1 Proteins 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 241000255601 Drosophila melanogaster Species 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 102100031780 Endonuclease Human genes 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
• 241000588914 Enterobacter Species 0.000 description 1
• 241000588921 Enterobacteriaceae Species 0.000 description 1
• 102400001368 Epidermal growth factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 102000056372 ErbB-3 Receptor Human genes 0.000 description 1
• 102000044591 ErbB-4 Receptor Human genes 0.000 description 1
• 241000588698 Erwinia Species 0.000 description 1
• 241000588722 Escherichia Species 0.000 description 1
• 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
• 108090000371 Esterases Proteins 0.000 description 1
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
• 229910052693 Europium Inorganic materials 0.000 description 1
• 101710082714 Exotoxin A Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 238000008416 Ferritin Methods 0.000 description 1
• 102000004641 Fetal Proteins Human genes 0.000 description 1
• 108010003471 Fetal Proteins Proteins 0.000 description 1
• 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
• 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
• 241000724791 Filamentous phage Species 0.000 description 1
• 108090000331 Firefly luciferases Proteins 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• 241000700662 Fowlpox virus Species 0.000 description 1
• 230000037057 G1 phase arrest Effects 0.000 description 1
• MVMSCBBUIHUTGJ-GDJBGNAASA-N GDP-alpha-D-mannose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=C(NC(=O)C=2N=C1)N)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O MVMSCBBUIHUTGJ-GDJBGNAASA-N 0.000 description 1
• 108010062427 GDP-mannose 4,6-dehydratase Proteins 0.000 description 1
• 102000002312 GDPmannose 4,6-dehydratase Human genes 0.000 description 1
• 229910052688 Gadolinium Inorganic materials 0.000 description 1
• 108010015133 Galactose oxidase Proteins 0.000 description 1
• 108010093031 Galactosidases Proteins 0.000 description 1
• 102000002464 Galactosidases Human genes 0.000 description 1
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
• 108700023863 Gene Components Proteins 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• 208000007465 Giant cell arteritis Diseases 0.000 description 1
• 102400000321 Glucagon Human genes 0.000 description 1
• 108060003199 Glucagon Proteins 0.000 description 1
• 102000030595 Glucokinase Human genes 0.000 description 1
• 108010021582 Glucokinase Proteins 0.000 description 1
• 239000004366 Glucose oxidase Substances 0.000 description 1
• 108010015776 Glucose oxidase Proteins 0.000 description 1
• 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
• 108010056771 Glucosidases Proteins 0.000 description 1
• 102000004366 Glucosidases Human genes 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
• JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
• 229930186217 Glycolipid Natural products 0.000 description 1
• 229940122069 Glycosidase inhibitor Drugs 0.000 description 1
• 102000051366 Glycosyltransferases Human genes 0.000 description 1
• 108700023372 Glycosyltransferases Proteins 0.000 description 1
• 206010018498 Goitre Diseases 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 108010069236 Goserelin Proteins 0.000 description 1
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
• 241000219146 Gossypium Species 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
• 101100508941 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) ppa gene Proteins 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 208000010496 Heart Arrest Diseases 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
• 102000005548 Hexokinase Human genes 0.000 description 1
• 108700040460 Hexokinases Proteins 0.000 description 1
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
• 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
• 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 1
• 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
• 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 1
• 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
• 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
• 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
• 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
• 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
• 101000984196 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 5 Proteins 0.000 description 1
• 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 description 1
• 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 description 1
• 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
• 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
• 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
• 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
• 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
• 241000701109 Human adenovirus 2 Species 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• 102000004867 Hydro-Lyases Human genes 0.000 description 1
• 108090001042 Hydro-Lyases Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
• 206010021263 IgA nephropathy Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108090000191 Inhibitor of growth protein 1 Proteins 0.000 description 1
• 102000003781 Inhibitor of growth protein 1 Human genes 0.000 description 1
• 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
• 102400000022 Insulin-like growth factor II Human genes 0.000 description 1
• 102100022338 Integrin alpha-M Human genes 0.000 description 1
• 102100022297 Integrin alpha-X Human genes 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 108090000177 Interleukin-11 Proteins 0.000 description 1
• 108010065805 Interleukin-12 Proteins 0.000 description 1
• 241000588748 Klebsiella Species 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
• JLERVPBPJHKRBJ-UHFFFAOYSA-N LY 117018 Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCC3)=CC=2)C2=CC=C(O)C=C2S1 JLERVPBPJHKRBJ-UHFFFAOYSA-N 0.000 description 1
• 241000481961 Lachancea thermotolerans Species 0.000 description 1
• 241000235651 Lachancea waltii Species 0.000 description 1
• 102100038609 Lactoperoxidase Human genes 0.000 description 1
• 108010023244 Lactoperoxidase Proteins 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
• SQECYPINZNWUTE-FXQIFTODSA-N Lentiginosine Chemical compound C1CCC[C@H]2[C@H](O)[C@@H](O)CN21 SQECYPINZNWUTE-FXQIFTODSA-N 0.000 description 1
• 229920001491 Lentinan Polymers 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 1
• 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 description 1
• 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
• 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 208000005777 Lupus Nephritis Diseases 0.000 description 1
• 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
• 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
• 101001133631 Lysinibacillus sphaericus Penicillin acylase Proteins 0.000 description 1
• 241000282553 Macaca Species 0.000 description 1
• 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
• 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102100025315 Mannosyl-oligosaccharide glucosidase Human genes 0.000 description 1
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
• VJRAUFKOOPNFIQ-UHFFFAOYSA-N Marcellomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CC(O)C(O)C(C)O1 VJRAUFKOOPNFIQ-UHFFFAOYSA-N 0.000 description 1
• 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
• 244000302512 Momordica charantia Species 0.000 description 1
• 235000009811 Momordica charantia Nutrition 0.000 description 1
• 102000013967 Monokines Human genes 0.000 description 1
• 108010050619 Monokines Proteins 0.000 description 1
• 102100030173 Muellerian-inhibiting factor Human genes 0.000 description 1
• 101710122877 Muellerian-inhibiting factor Proteins 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 108010085220 Multiprotein Complexes Proteins 0.000 description 1
• 102000007474 Multiprotein Complexes Human genes 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 101100502522 Mus musculus Fcor gene Proteins 0.000 description 1
• 206010028424 Myasthenic syndrome Diseases 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
• SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
• AAKDPDFZMNYDLR-UHFFFAOYSA-N N-methyl deoxynojirimycin Natural products CN1CC(O)C(O)C(O)C1CO AAKDPDFZMNYDLR-UHFFFAOYSA-N 0.000 description 1
• AAKDPDFZMNYDLR-XZBKPIIZSA-N N-methyl-1-deoxynojirimycin Chemical compound CN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO AAKDPDFZMNYDLR-XZBKPIIZSA-N 0.000 description 1
• WTBIAPVQQBCLFP-UHFFFAOYSA-N N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O Chemical compound N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O WTBIAPVQQBCLFP-UHFFFAOYSA-N 0.000 description 1
• 206010061309 Neoplasm progression Diseases 0.000 description 1
• 102000015336 Nerve Growth Factor Human genes 0.000 description 1
• 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
• 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
• 108010006232 Neuraminidase Proteins 0.000 description 1
• 102000005348 Neuraminidase Human genes 0.000 description 1
• 206010029240 Neuritis Diseases 0.000 description 1
• 241000221960 Neurospora Species 0.000 description 1
• 241000221961 Neurospora crassa Species 0.000 description 1
• 108090000095 Neurotrophin-6 Proteins 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
• KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
• 108091060545 Nonsense suppressor Proteins 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 229930187135 Olivomycin Natural products 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• 102100021079 Ornithine decarboxylase Human genes 0.000 description 1
• 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
• 101100081884 Oryza sativa subsp. japonica OSA15 gene Proteins 0.000 description 1
• 101150082245 PSAG gene Proteins 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 108010067372 Pancreatic elastase Proteins 0.000 description 1
• 102000016387 Pancreatic elastase Human genes 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 108010073038 Penicillin Amidase Proteins 0.000 description 1
• 101710123388 Penicillin G acylase Proteins 0.000 description 1
• 108010087702 Penicillinase Proteins 0.000 description 1
• 241000228143 Penicillium Species 0.000 description 1
• 108010057150 Peplomycin Proteins 0.000 description 1
• 102000015731 Peptide Hormones Human genes 0.000 description 1
• 108010038988 Peptide Hormones Proteins 0.000 description 1
• 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
• 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 240000007377 Petunia x hybrida Species 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 102000001105 Phosphofructokinases Human genes 0.000 description 1
• 108010069341 Phosphofructokinases Proteins 0.000 description 1
• 108010089430 Phosphoproteins Proteins 0.000 description 1
• 102000007982 Phosphoproteins Human genes 0.000 description 1
• 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
• 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
• 108010003044 Placental Lactogen Proteins 0.000 description 1
• 239000000381 Placental Lactogen Substances 0.000 description 1
• 102000013566 Plasminogen Human genes 0.000 description 1
• 108010051456 Plasminogen Proteins 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 229920000805 Polyaspartic acid Polymers 0.000 description 1
• 206010036105 Polyneuropathy Diseases 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 102100025067 Potassium voltage-gated channel subfamily H member 4 Human genes 0.000 description 1
• 101710163352 Potassium voltage-gated channel subfamily H member 4 Proteins 0.000 description 1
• HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
• 102000003946 Prolactin Human genes 0.000 description 1
• 108010057464 Prolactin Proteins 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 241000588769 Proteus <enterobacteria> Species 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• 108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
• 102000013009 Pyruvate Kinase Human genes 0.000 description 1
• 108020005115 Pyruvate Kinase Proteins 0.000 description 1
• 102000004879 Racemases and epimerases Human genes 0.000 description 1
• 108090001066 Racemases and epimerases Proteins 0.000 description 1
• AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
• 244000088415 Raphanus sativus Species 0.000 description 1
• 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
• 241000700157 Rattus norvegicus Species 0.000 description 1
• 230000010799 Receptor Interactions Effects 0.000 description 1
• 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
• 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 108090000103 Relaxin Proteins 0.000 description 1
• 102000003743 Relaxin Human genes 0.000 description 1
• 102400000834 Relaxin A chain Human genes 0.000 description 1
• 101800000074 Relaxin A chain Proteins 0.000 description 1
• 102400000610 Relaxin B chain Human genes 0.000 description 1
• 101710109558 Relaxin B chain Proteins 0.000 description 1
• 108090000783 Renin Proteins 0.000 description 1
• 102100028255 Renin Human genes 0.000 description 1
• PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
• 241000219061 Rheum Species 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 241000714474 Rous sarcoma virus Species 0.000 description 1
• 241000235070 Saccharomyces Species 0.000 description 1
• 206010061934 Salivary gland cancer Diseases 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
• 108010084592 Saporins Proteins 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
• 241000311088 Schwanniomyces Species 0.000 description 1
• 241001123650 Schwanniomyces occidentalis Species 0.000 description 1
• 108090000184 Selectins Proteins 0.000 description 1
• 102000003800 Selectins Human genes 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• 239000012507 Sephadex™ Substances 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 241000607768 Shigella Species 0.000 description 1
• 102000003838 Sialyltransferases Human genes 0.000 description 1
• 108090000141 Sialyltransferases Proteins 0.000 description 1
• 102100038081 Signal transducer CD24 Human genes 0.000 description 1
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
• 229920000519 Sizofiran Polymers 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 239000004268 Sodium erythorbin Substances 0.000 description 1
• 240000003768 Solanum lycopersicum Species 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 102100022831 Somatoliberin Human genes 0.000 description 1
• 101710142969 Somatoliberin Proteins 0.000 description 1
• 241000862969 Stella Species 0.000 description 1
• 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 241000187747 Streptomyces Species 0.000 description 1
• 108090000787 Subtilisin Proteins 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 102000019197 Superoxide Dismutase Human genes 0.000 description 1
• 108010012715 Superoxide dismutase Proteins 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
• CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 1
• 241000255588 Tephritidae Species 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 108090001109 Thermolysin Proteins 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 108010034949 Thyroglobulin Proteins 0.000 description 1
• 102000009843 Thyroglobulin Human genes 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
• 241001149964 Tolypocladium Species 0.000 description 1
• IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
• 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• 241000223259 Trichoderma Species 0.000 description 1
• UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
• 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
• 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• 229940122618 Trypsin inhibitor Drugs 0.000 description 1
• 101710162629 Trypsin inhibitor Proteins 0.000 description 1
• 241000722921 Tulipa gesneriana Species 0.000 description 1
• 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
• 206010054094 Tumour necrosis Diseases 0.000 description 1
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
• 108091023045 Untranslated Region Proteins 0.000 description 1
• 108010092464 Urate Oxidase Proteins 0.000 description 1
• 108010046334 Urease Proteins 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 241000863480 Vinca Species 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 206010047741 Vulval cancer Diseases 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 102100033220 Xanthine oxidase Human genes 0.000 description 1
• 108010093894 Xanthine oxidase Proteins 0.000 description 1
• 241000235013 Yarrowia Species 0.000 description 1
• VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• ZYVSOIYQKUDENJ-ASUJBHBQSA-N [(2R,3R,4R,6R)-6-[[(6S,7S)-6-[(2S,4R,5R,6R)-4-[(2R,4R,5R,6R)-4-[(2S,4S,5S,6S)-5-acetyloxy-4-hydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-7-[(3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-4,10-dihydroxy-3-methyl-5-oxo-7,8-dihydro-6H-anthracen-2-yl]oxy]-4-[(2R,4R,5R,6R)-4-hydroxy-5-methoxy-6-methyloxan-2-yl]oxy-2-methyloxan-3-yl] acetate Chemical class COC([C@@H]1Cc2cc3cc(O[C@@H]4C[C@@H](O[C@@H]5C[C@@H](O)[C@@H](OC)[C@@H](C)O5)[C@H](OC(C)=O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@@H](OC(C)=O)[C@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O ZYVSOIYQKUDENJ-ASUJBHBQSA-N 0.000 description 1
• SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
• IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
• IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 1
• XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
• 229960000446 abciximab Drugs 0.000 description 1
• 208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• MNOGBRROKHFONU-CJUKMMNNSA-N ac1l2wzw Chemical compound C1N2C(C(C(C)=C(NCCOP(O)(O)=O)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 MNOGBRROKHFONU-CJUKMMNNSA-N 0.000 description 1
• ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
• 229950002684 aceglatone Drugs 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 239000003929 acidic solution Substances 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 206010000891 acute myocardial infarction Diseases 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 229960005305 adenosine Drugs 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000009824 affinity maturation Effects 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 230000004931 aggregating effect Effects 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 150000001294 alanine derivatives Chemical group 0.000 description 1
• 238000012867 alanine scanning Methods 0.000 description 1
• 208000002353 alcoholic hepatitis Diseases 0.000 description 1
• 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
• 150000008052 alkyl sulfonates Chemical class 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• 150000001371 alpha-amino acids Chemical class 0.000 description 1
• 235000008206 alpha-amino acids Nutrition 0.000 description 1
• 108010001818 alpha-sarcin Proteins 0.000 description 1
• 229960000473 altretamine Drugs 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• 238000005576 amination reaction Methods 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229960003437 aminoglutethimide Drugs 0.000 description 1
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
• 229960002749 aminolevulinic acid Drugs 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 229960001220 amsacrine Drugs 0.000 description 1
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
• BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
• 229950000242 ancitabine Drugs 0.000 description 1
• 229940030486 androgens Drugs 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 239000003957 anion exchange resin Substances 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000002280 anti-androgenic effect Effects 0.000 description 1
• 230000001455 anti-clotting effect Effects 0.000 description 1
• 230000002391 anti-complement effect Effects 0.000 description 1
• 229940046836 anti-estrogen Drugs 0.000 description 1
• 230000001833 anti-estrogenic effect Effects 0.000 description 1
• 230000003602 anti-herpes Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 239000000868 anti-mullerian hormone Substances 0.000 description 1
• 230000001475 anti-trypsic effect Effects 0.000 description 1
• 239000000051 antiandrogen Substances 0.000 description 1
• 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
• 108010008730 anticomplement Proteins 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 239000013059 antihormonal agent Substances 0.000 description 1
• 230000009876 antimalignant effect Effects 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 238000003782 apoptosis assay Methods 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 150000008209 arabinosides Chemical class 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• 229960002756 azacitidine Drugs 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 229950011321 azaserine Drugs 0.000 description 1
• 150000001541 aziridines Chemical class 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
• 229960001950 benzethonium chloride Drugs 0.000 description 1
• UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• CXQCLLQQYTUUKJ-ALWAHNIESA-N beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp-(1<->1')-Cer(d18:1/18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@@H](CO)O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 CXQCLLQQYTUUKJ-ALWAHNIESA-N 0.000 description 1
• 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
• 102000006635 beta-lactamase Human genes 0.000 description 1
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
• 229960000997 bicalutamide Drugs 0.000 description 1
• 238000013357 binding ELISA Methods 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
• 229950008548 bisantrene Drugs 0.000 description 1
• 201000000053 blastoma Diseases 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 239000012503 blood component Substances 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 208000006752 brain edema Diseases 0.000 description 1
• 210000000069 breast epithelial cell Anatomy 0.000 description 1
• 201000009267 bronchiectasis Diseases 0.000 description 1
• 206010006451 bronchitis Diseases 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 108700002839 cactinomycin Proteins 0.000 description 1
• 229950009908 cactinomycin Drugs 0.000 description 1
• 229960004015 calcitonin Drugs 0.000 description 1
• BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 244000309466 calf Species 0.000 description 1
• 229950009823 calusterone Drugs 0.000 description 1
• IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 229960002115 carboquone Drugs 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 238000007675 cardiac surgery Methods 0.000 description 1
• 229930188550 carminomycin Natural products 0.000 description 1
• XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
• XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
• 229960003261 carmofur Drugs 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
• 229950001725 carubicin Drugs 0.000 description 1
• 108010047060 carzinophilin Proteins 0.000 description 1
• 239000003729 cation exchange resin Substances 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 230000006369 cell cycle progression Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000009134 cell regulation Effects 0.000 description 1
• 230000008614 cellular interaction Effects 0.000 description 1
• 230000004700 cellular uptake Effects 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 229960001480 chlorozotocin Drugs 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 230000010428 chromatin condensation Effects 0.000 description 1
• 238000011098 chromatofocusing Methods 0.000 description 1
• 239000013611 chromosomal DNA Substances 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 208000007451 chronic bronchitis Diseases 0.000 description 1
• 230000012085 chronic inflammatory response Effects 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 229940080701 chymosin Drugs 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 238000004737 colorimetric analysis Methods 0.000 description 1
• 230000001447 compensatory effect Effects 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 239000005289 controlled pore glass Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 238000007887 coronary angioplasty Methods 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 230000005574 cross-species transmission Effects 0.000 description 1
• 238000012866 crystallographic experiment Methods 0.000 description 1
• HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 229960003067 cystine Drugs 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 230000001461 cytolytic effect Effects 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 230000001085 cytostatic effect Effects 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000003413 degradative effect Effects 0.000 description 1
• 229960005052 demecolcine Drugs 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 108700001680 des-(1-3)- insulin-like growth factor 1 Proteins 0.000 description 1
• 229950003913 detorubicin Drugs 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 229930191339 dianthin Natural products 0.000 description 1
• WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
• 229950002389 diaziquone Drugs 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 206010062952 diffuse panbronchiolitis Diseases 0.000 description 1
• LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
• LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
• 230000010339 dilation Effects 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 230000003467 diminishing effect Effects 0.000 description 1
• 206010013023 diphtheria Diseases 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
• 229950005454 doxifluridine Drugs 0.000 description 1
• NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
• 229950004683 drostanolone propionate Drugs 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
• 229960002759 eflornithine Drugs 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 229950000549 elliptinium acetate Drugs 0.000 description 1
• 201000008184 embryoma Diseases 0.000 description 1
• 201000003914 endometrial carcinoma Diseases 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 229950011487 enocitabine Drugs 0.000 description 1
• 108010028531 enomycin Proteins 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 229950002973 epitiostanol Drugs 0.000 description 1
• 229960001433 erlotinib Drugs 0.000 description 1
• 229950002017 esorubicin Drugs 0.000 description 1
• ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 229960001842 estramustine Drugs 0.000 description 1
• FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• 239000000328 estrogen antagonist Substances 0.000 description 1
• 238000012869 ethanol precipitation Methods 0.000 description 1
• QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2s)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 description 1
• 229960005237 etoglucid Drugs 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 229960000301 factor viii Drugs 0.000 description 1
• 229940043168 fareston Drugs 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 239000003527 fibrinolytic agent Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 229960000961 floxuridine Drugs 0.000 description 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 229960000304 folic acid Drugs 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 150000002224 folic acids Chemical class 0.000 description 1
• 229960004783 fotemustine Drugs 0.000 description 1
• YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 235000021588 free fatty acids Nutrition 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 230000033581 fucosylation Effects 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 229940044658 gallium nitrate Drugs 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 238000003500 gene array Methods 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 102000034356 gene-regulatory proteins Human genes 0.000 description 1
• 108091006104 gene-regulatory proteins Proteins 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 102000018146 globin Human genes 0.000 description 1
• 108060003196 globin Proteins 0.000 description 1
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
• 229960004666 glucagon Drugs 0.000 description 1
• 229940116332 glucose oxidase Drugs 0.000 description 1
• 235000019420 glucose oxidase Nutrition 0.000 description 1
• 150000002304 glucoses Chemical group 0.000 description 1
• 108010050669 glucosidase I Proteins 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 230000002414 glycolytic effect Effects 0.000 description 1
• 150000002337 glycosamines Chemical class 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 230000001279 glycosylating effect Effects 0.000 description 1
• 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
• 201000003872 goiter Diseases 0.000 description 1
• 229960002913 goserelin Drugs 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 108010067006 heat stable toxin (E coli) Proteins 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 208000007475 hemolytic anemia Diseases 0.000 description 1
• 230000002607 hemopoietic effect Effects 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• 125000000623 heterocyclic group Chemical group 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 238000001794 hormone therapy Methods 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 230000008348 humoral response Effects 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 229920001477 hydrophilic polymer Polymers 0.000 description 1
• 229920001600 hydrophobic polymer Polymers 0.000 description 1
• 229960001330 hydroxycarbamide Drugs 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 229940015872 ibandronate Drugs 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000014726 immortalization of host cell Effects 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 230000002998 immunogenetic effect Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 229940027941 immunoglobulin g Drugs 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 230000002134 immunopathologic effect Effects 0.000 description 1
• 230000003116 impacting effect Effects 0.000 description 1
• DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
• 229950008097 improsulfan Drugs 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
• 229940055742 indium-111 Drugs 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 238000007689 inspection Methods 0.000 description 1
• 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
• 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000001573 invertase Substances 0.000 description 1
• 235000011073 invertase Nutrition 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 229940084651 iressa Drugs 0.000 description 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
• 229940057428 lactoperoxidase Drugs 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 238000011031 large-scale manufacturing process Methods 0.000 description 1
• 229940115286 lentinan Drugs 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
• 108020001756 ligand binding domains Proteins 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 229960003538 lonidamine Drugs 0.000 description 1
• WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
• 201000005249 lung adenocarcinoma Diseases 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 229940087857 lupron Drugs 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 210000005210 lymphoid organ Anatomy 0.000 description 1
• 239000004325 lysozyme Substances 0.000 description 1
• 229960000274 lysozyme Drugs 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 229910052748 manganese Inorganic materials 0.000 description 1
• 239000011572 manganese Substances 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
• 229950008612 mannomustine Drugs 0.000 description 1
• 108010083819 mannosyl-oligosaccharide 1,3 - 1,6-alpha-mannosidase Proteins 0.000 description 1
• 238000005621 mannosylation reaction Methods 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000008774 maternal effect Effects 0.000 description 1
• 210000003519 mature b lymphocyte Anatomy 0.000 description 1
• 239000012092 media component Substances 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229950009246 mepitiostane Drugs 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Chemical class 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• VJRAUFKOOPNFIQ-TVEKBUMESA-N methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylat Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 VJRAUFKOOPNFIQ-TVEKBUMESA-N 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 238000012737 microarray-based gene expression Methods 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 108010029942 microperoxidase Proteins 0.000 description 1
• 229960005485 mitobronitol Drugs 0.000 description 1
• 229960003539 mitoguazone Drugs 0.000 description 1
• MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
• VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
• 229950010913 mitolactol Drugs 0.000 description 1
• 229960000350 mitotane Drugs 0.000 description 1
• 229950003063 mitumomab Drugs 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 108010010621 modeccin Proteins 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
• 229950010718 mopidamol Drugs 0.000 description 1
• 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 1
• UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
• NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 229940086322 navelbine Drugs 0.000 description 1
• QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
• 201000008383 nephritis Diseases 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 229940032018 neurotrophin 3 Drugs 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 230000011242 neutrophil chemotaxis Effects 0.000 description 1
• XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
• 229960002653 nilutamide Drugs 0.000 description 1
• 229960001420 nimustine Drugs 0.000 description 1
• VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
• YMVWGSQGCWCDGW-UHFFFAOYSA-N nitracrine Chemical compound C1=CC([N+]([O-])=O)=C2C(NCCCN(C)C)=C(C=CC=C3)C3=NC2=C1 YMVWGSQGCWCDGW-UHFFFAOYSA-N 0.000 description 1
• 229950008607 nitracrine Drugs 0.000 description 1
• 229950009266 nogalamycin Drugs 0.000 description 1
• KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 230000001293 nucleolytic effect Effects 0.000 description 1
• CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical class O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
• 229950011093 onapristone Drugs 0.000 description 1
• 229950007283 oregovomab Drugs 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 229950009506 penicillinase Drugs 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
• 229950003180 peplomycin Drugs 0.000 description 1
• 239000000813 peptide hormone Substances 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 125000001151 peptidyl group Chemical group 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 201000002628 peritoneum cancer Diseases 0.000 description 1
• 230000002688 persistence Effects 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 108010076042 phenomycin Proteins 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
• 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 229960000952 pipobroman Drugs 0.000 description 1
• NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
• NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
• 229950001100 piposulfan Drugs 0.000 description 1
• 229960001221 pirarubicin Drugs 0.000 description 1
• 101150008001 pl gene Proteins 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 150000003057 platinum Chemical class 0.000 description 1
• 208000008423 pleurisy Diseases 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 108010064470 polyaspartate Proteins 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
• 230000007824 polyneuropathy Effects 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 229960004694 prednimustine Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 108010066381 preproinsulin Proteins 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• 230000005522 programmed cell death Effects 0.000 description 1
• 229940097325 prolactin Drugs 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000012743 protein tagging Effects 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 238000003127 radioimmunoassay Methods 0.000 description 1
• 229960002185 ranimustine Drugs 0.000 description 1
• 229910052761 rare earth metal Inorganic materials 0.000 description 1
• 150000002910 rare earth metals Chemical class 0.000 description 1
• BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
• 229960000460 razoxane Drugs 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000022983 regulation of cell cycle Effects 0.000 description 1
• 229940116176 remicade Drugs 0.000 description 1
• 229940107685 reopro Drugs 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 229930002330 retinoic acid Natural products 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 229950004892 rodorubicin Drugs 0.000 description 1
• 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
• VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
• 201000003804 salivary gland carcinoma Diseases 0.000 description 1
• 238000003345 scintillation counting Methods 0.000 description 1
• HOZOZZFCZRXYEK-HNHWXVNLSA-M scopolamine butylbromide Chemical compound [Br-].C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-HNHWXVNLSA-M 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 210000000717 sertoli cell Anatomy 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 235000021309 simple sugar Nutrition 0.000 description 1
• 229940115586 simulect Drugs 0.000 description 1
• 230000003007 single stranded DNA break Effects 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 229950001403 sizofiran Drugs 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 229960000553 somatostatin Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 238000010183 spectrum analysis Methods 0.000 description 1
• 238000009987 spinning Methods 0.000 description 1
• 229950006315 spirogermanium Drugs 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 208000017572 squamous cell neoplasm Diseases 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 238000011146 sterile filtration Methods 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 229940014800 succinic anhydride Drugs 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 108060007951 sulfatase Proteins 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 238000004114 suspension culture Methods 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 229960005566 swainsonine Drugs 0.000 description 1
• FXUAIOOAOAVCGD-UHFFFAOYSA-N swainsonine Natural products C1CCC(O)C2C(O)C(O)CN21 FXUAIOOAOAVCGD-UHFFFAOYSA-N 0.000 description 1
• FXUAIOOAOAVCGD-FKSUSPILSA-N swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 229940036185 synagis Drugs 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
• 229940063683 taxotere Drugs 0.000 description 1
• 206010043207 temporal arteritis Diseases 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 229960005353 testolactone Drugs 0.000 description 1
• BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 229960002175 thyroglobulin Drugs 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 229940034208 thyroxine Drugs 0.000 description 1
• XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
• YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
• 229950011457 tiamiprine Drugs 0.000 description 1
• RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
• 229960005026 toremifene Drugs 0.000 description 1
• 230000007888 toxin activity Effects 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 229960000575 trastuzumab Drugs 0.000 description 1
• 229950001353 tretamine Drugs 0.000 description 1
• IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
• 229960004560 triaziquone Drugs 0.000 description 1
• 229960001670 trilostane Drugs 0.000 description 1
• KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
• NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
• 229960001099 trimetrexate Drugs 0.000 description 1
• 229950000212 trioxifene Drugs 0.000 description 1
• 229960000875 trofosfamide Drugs 0.000 description 1
• UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
• 101150108727 trpl gene Proteins 0.000 description 1
• HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 230000005751 tumor progression Effects 0.000 description 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
• 108010087967 type I signal peptidase Proteins 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 229950009811 ubenimex Drugs 0.000 description 1
• 229960001055 uracil mustard Drugs 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 229960005356 urokinase Drugs 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 208000012991 uterine carcinoma Diseases 0.000 description 1
• 239000012646 vaccine adjuvant Substances 0.000 description 1
• 229940124931 vaccine adjuvant Drugs 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 201000005102 vulva cancer Diseases 0.000 description 1
• 239000011534 wash buffer Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• XLYOFNOQVPJJNP-OUBTZVSYSA-N water-17o Chemical compound [17OH2] XLYOFNOQVPJJNP-OUBTZVSYSA-N 0.000 description 1
• 229940053867 xeloda Drugs 0.000 description 1
• 229950009268 zinostatin Drugs 0.000 description 1
• 229960000641 zorubicin Drugs 0.000 description 1
• FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1